A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte Allerton(Pfizer (United States)), Yuao Zhu(Pfizer (United States))
Cited by 67
Related Papers
Designing small molecules for therapeutic success: A contemporary perspective
|Drug Discovery Today|2021|38